Key result
TAK-242 significantly improved CME-induced cardiac dysfunction, reduced micro-infarction area, and decreased the apoptotic index compared to CME alone (P < 0.05).
Why the study?
Does TAK-242 improve cardiac function and reduce myocardial apoptosis in a rat model of coronary microembolization?
Population
45 rats, coronary microembolization model induced by injecting polyethylene microspheres into the left…
Comparison
TAK-242 administered via the tail vein 30… vs CME without TAK-242, and sham operation
Design
Preclinical, randomized (random number)
Follow-up
6 hours
Authors
Loading...
Should not change clinical practice in CME; hypothesis-generating for TLR4-targeted therapy in larger models.
RCT (n=45)
random number
Does TAK-242 improve cardiac function and reduce myocardial apoptosis in a rat model of coronary microembolization?
p-value: p=< 0.05
TAK-242 protects against coronary microembolization-induced myocardial injury in rats by inhibiting the TLR4/NF-κB signaling pathway.
Wang et al. (2017) conducted an RCT in Coronary microembolization-induced myocardial injury (n=45). TAK-242 vs. Coronary microembolization (CME) alone was evaluated on Cardiac function, micro-infarction area, and myocardial apoptosis (p=< 0.05). TAK-242 significantly improved CME-induced cardiac dysfunction, reduced micro-infarction area, and decreased the apoptotic index compared to CME alone (P < 0.05).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: